Today: 28 June 2026
Browse Category

NYSE:ABBV 23 August 2025 - 13 December 2025

AbbVie Stock (ABBV) After-Hours Update: What Happened on Dec. 12, 2025—and What to Watch Before the Next Market Open

AbbVie Stock (ABBV) After-Hours Update: What Happened on Dec. 12, 2025—and What to Watch Before the Next Market Open

AbbVie shares closed at $223.32 Friday, down 0.29%, and slipped further to $222.52 in after-hours trading. Morgan Stanley raised its price target on AbbVie to $269 from $261 while maintaining an Overweight rating. U.S. indexes fell broadly, with the S&P 500 down 1.07% and the Nasdaq off 1.69%. After-hours ABBV volume reached about 529,700 shares by 6:25 p.m. EST.
13 December 2025
·
AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie shares rebounded 2.98% to $236.28 on Nov. 21, 2025, with trading volume spiking to 7.9 million after three down days. Year-to-date, the stock is up about 22–26%, outpacing the S&P 500, but remains 7–9% below its October high. Forward P/E estimates range from 16x to 22x. Investors weigh strong Skyrizi and Rinvoq sales against Humira declines and regulatory risk.
11 December 2025
···
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie shares closed near $225 on December 1, 2025, valuing the company at about $400 billion. Q3 net revenue rose 9.1% to $15.78 billion, with adjusted EPS of $1.86 topping estimates. The company raised its 2025 profit forecast and approved a 5.5% dividend increase. Immunology sales climbed, while Humira revenue dropped below $1 billion.
1 December 2025
····
AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

AbbVie closed November 30 at about $227, down 3% for the week but up over 30% in the past year. Shares slipped after news of steep Medicare price cuts for Linzess and Vraylar, while Canada approved public reimbursement for Skyrizi. AbbVie raised its 2026 dividend by 5.5%, with a forward yield just above 3%. Wall Street’s 12-month price target averages $240–$247.
30 November 2025
·
AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength

AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength

AbbVie shares closed November at about $227, up 32% year to date but down 3% for the week amid Medicare pricing pressures. The stock’s trailing P/E remains above 170 due to one-off charges, while forward P/E is in the mid-teens. Wall Street Zen downgraded AbbVie from “Strong Buy” to “Buy” on November 30. The average analyst price target sits in the mid-$240s.
30 November 2025
·
AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie shares closed at $227.70 on November 28, near record highs after a 31.7% year-to-date gain. The company secured a major reimbursement win in Canada for Skyrizi in ulcerative colitis. Institutional investors reported changes in AbbVie holdings. Analysts questioned whether the stock remains undervalued after its recent rally.
29 November 2025
···
AbbVie Stock (ABBV) Today: Skyrizi’s Canada Win, Dividend Hike and Big-Money Moves — November 28, 2025

AbbVie Stock (ABBV) Today: Skyrizi’s Canada Win, Dividend Hike and Big-Money Moves — November 28, 2025

AbbVie closed Friday at $227.70, up 0.02% after a flat session. Canada’s drug agency recommended reimbursement for Skyrizi in ulcerative colitis, and AbbVie finalized a pricing deal with the national negotiator. Institutional investors adjusted positions, with some funds increasing and others reducing stakes. The stock’s year-to-date gain stands near 30–33%.
28 November 2025
·
AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie shares fell 1.9% to $227.41 in early U.S. trading Wednesday, pulling back from recent highs after a strong run. The drop follows new Medicare drug price cuts targeting two AbbVie drugs and comes days after FDA approval of EPKINLY combo therapy for follicular lymphoma. Year to date, the stock is up about 30%.
26 November 2025
··
AbbVie (ABBV) Stock Today: Price, Analyst Views, Medicare News and New Biotech Award – November 25, 2025

AbbVie (ABBV) Stock Today: Price, Analyst Views, Medicare News and New Biotech Award – November 25, 2025

AbbVie shares closed at $231.80 on Tuesday, up 1.0%, after U.S. Medicare confirmed plans to negotiate prices on 15 drugs, including AbbVie’s Linzess. The stock saw higher-than-average volume and remains about 5% below its 52-week high. Analysts gave mixed views, with a “Moderate Buy” consensus and a $241.85 average price target. AbbVie also launched a new biotech award program in Quebec.
25 November 2025
·
AbbVie Stock Today (ABBV): Near Record Highs on New Cancer Approval, Raised Guidance and Dividend Hike – November 23, 2025

AbbVie Stock Today (ABBV): Near Record Highs on New Cancer Approval, Raised Guidance and Dividend Hike – November 23, 2025

AbbVie closed at $236.28 on November 21, 2025, near its 52-week high and up about 31% year to date. Q3 revenue rose 9.1% to $15.8 billion, led by immunology and neuroscience, while GAAP EPS dropped sharply due to a $2.7 billion R&D charge. The FDA granted full approval for EPKINLY in follicular lymphoma on November 18. AbbVie raised its 2025 revenue and EPS guidance and approved a 5.5% dividend hike for 2026.
23 November 2025
··
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Stock Market Today (Nov. 11, 2025): Dow Closes at a Record as AI Shares Stumble; FTSE 100 Hits New High on BoE Cut Bets

The Dow Jones closed at a record 47,927.96 on Nov. 11, 2025, up 1.18%, while the Nasdaq fell 0.25% as Nvidia dropped nearly 3% after SoftBank revealed a $5.8 billion stake sale. The S&P 500 edged higher. In Europe, the FTSE 100 hit a record near 9,900, boosted by Vodafone’s first dividend increase in eight years and rising bets on Bank of England rate cuts.
11 November 2025
········
AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie reported Q3 2025 revenue of $15.78 billion, up 9.1% year-over-year, and raised its full-year EPS outlook after new drugs offset Humira’s decline. Shares traded near $228 in late October, up 28% year-to-date, and the board approved a 5.5% dividend increase for 2026. Skyrizi and Rinvoq sales surged, while the FDA expanded Rinvoq’s indications. AbbVie also announced over $10 billion in acquisitions and new manufacturing investments.
31 October 2025
··
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism

AbbVie shares trade near $229, up 28% year-to-date and outperforming the S&P 500 healthcare index. The stock hit a record high in late September after a patent settlement extended U.S. exclusivity for Rinvoq until 2037. AbbVie announced a $2.7 billion R&D write-off in October, cutting profit guidance. FDA expanded Rinvoq’s use Oct. 13; a recent trial showed Rinvoq outperformed Humira in rheumatoid arthritis.
23 October 2025
·
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 20.10.2025

Fed Chair Jerome Powell signaled the central bank may soon pause its balance-sheet runoff, hinting at an end to quantitative tightening. The move could ease monetary conditions and support stocks, though risks remain if earnings weaken. AbbVie and Abbott Laboratories continue to deliver steady dividend growth, appealing to long-term income investors. Walmart’s new OpenAI partnership and AI-driven features have lifted its shares despite sector headwinds.
20 October 2025
···
Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Eli Lilly’s oral weight-loss drug orforglipron cut body weight by up to 10.5% in a Phase 3 trial for obese diabetics, with all doses meeting primary endpoints over 72 weeks. The FDA granted full approval to Precigen’s Papzimeos, the first gene therapy for adult recurrent respiratory papillomatosis. AbbVie agreed to acquire a psychedelic-based depression drug from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion.
27 August 2025
·····
Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

AbbVie agreed to acquire Gilgamesh Pharmaceuticals’ experimental psychedelic depression drug for up to $1.2 billion, planning to advance it to Phase 3 trials. Japan’s Terumo will buy UK-based OrganOx for $1.5 billion, gaining organ preservation technology. LB Pharma filed for a $100 million IPO, the first biotech IPO in six months. Arnatar Therapeutics raised $52 million to develop RNA therapy for Alagille syndrome.
26 August 2025
··
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.
23 August 2025
·······
1 … 3 4 5 6

Stock Market Today

  • Financial Media Stocks Linked to Market-Moving News Flow
    June 28, 2026, 2:53 PM EDT. Financial media companies wield significant influence on market sentiment by rapidly disseminating news. Investors eye firms that collect and distribute this information, as their valuations often hinge on shifts in audience attention and news catalysts. Australian firms HMC Capital (ASX:HMC) and Navigator Global Investments (ASX:NGI) represent notable examples. HMC Capital focuses on real estate, digital infrastructure, and private credit, but remains loss-making and faces execution risks despite optimistic earnings forecasts. Navigator Global Investments offers access to alternative strategies including hedge funds and private equity, driving revenue primarily through its Lighthouse segment. These firms highlight how information flow intersects with investment products, creating both opportunities and risks for market participants.

Latest articles

Opendoor volume surpasses short interest after Russell 3000 addition

Opendoor shares face Russell 3000 test after 4.5x volume spike

28 June 2026
Opendoor Technologies (NASDAQ:OPEN) surged 448% above average trading volume Friday as its Russell 3000 inclusion took effect, with 171.65 million shares traded—exceeding total short interest and equaling 21% of public float—while the stock closed up 1.63% at $4.37; analysts maintain a Hold consensus and see limited rally potential near current prices.
Coeur Mining shares eye index-driven moves after 8.5% weekly slide

Coeur Mining shares eye index-driven moves after 8.5% weekly slide

28 June 2026
Coeur Mining (NYSE:CDE) ended its first week in the S&P MidCap 400 down 8.5% from June 18, despite Friday’s massive $2.7 billion volume—about 16% of its market cap—highlighting investor caution after recent acquisitions and index changes, as the stock lagged silver-miner peers even with a record quarter expected.
Go toTop